BeiGene and Springworks Therapeutics are Collaborating to Research a Combination Therapy for Advanced Solid Tumours
stevepb / Pixabay

BeiGene and Springworks Therapeutics are Collaborating to Research a Combination Therapy for Advanced Solid Tumours

The companies BeiGene Ltd. and SpringWorks Therapeutics have announced that they will collaborate to research the safety and preliminary efficacy of a combination of two drugs: BeiGene’s investigational drug lifirafenib…

Continue Reading BeiGene and Springworks Therapeutics are Collaborating to Research a Combination Therapy for Advanced Solid Tumours
Two Clinical Studies of Enzalutamide in Hormone-Sensitive Prostate Cancer Have Been Amended
DarkoStojanovic / Pixabay

Two Clinical Studies of Enzalutamide in Hormone-Sensitive Prostate Cancer Have Been Amended

Two clinical trials have had their study protocols amended, announces Pfizer and Astellas Pharma. The Phase 3 trials, called ‘Arches’ and ‘Embark’, will investigate the safety and effectiveness of the…

Continue Reading Two Clinical Studies of Enzalutamide in Hormone-Sensitive Prostate Cancer Have Been Amended
Treatment for Childhood and Spinal Cord Cancer Linked to Lower Levels of Independence for Survivors
12019 / Pixabay

Treatment for Childhood and Spinal Cord Cancer Linked to Lower Levels of Independence for Survivors

  The survival rates for infants and children with brain and spinal cord cancer has improved significantly over the past decades. However, a study published online in early August of…

Continue Reading Treatment for Childhood and Spinal Cord Cancer Linked to Lower Levels of Independence for Survivors
An Experimental Drug Combination Treatment for Certain Bowel Cancers Has Been Granted Breakthrough Therapy Designation
stevepb / Pixabay

An Experimental Drug Combination Treatment for Certain Bowel Cancers Has Been Granted Breakthrough Therapy Designation

The US FDA has awarded Breakthrough Therapy Designation to encorafenib (braftoviTM) combined with binimetinib (mektovi®) and cetuximab for use as an investigational (not FDA-approved) treatment of BRAFV600E–mutant metastatic colorectal cancer.…

Continue Reading An Experimental Drug Combination Treatment for Certain Bowel Cancers Has Been Granted Breakthrough Therapy Designation
A Combination of Arsenic with Another Drug May Have the Potential to Treat Cancer, Researchers Say
felixioncool / Pixabay

A Combination of Arsenic with Another Drug May Have the Potential to Treat Cancer, Researchers Say

A research team led by scientists from the Beth Israel Deaconess Medical Center (BIDMC) have found that arsenic, in combination with the drug all-trans retinoic acid (ATRA), may have the potential…

Continue Reading A Combination of Arsenic with Another Drug May Have the Potential to Treat Cancer, Researchers Say
A Planned Study Will Investigate the Effects of an Investigational Drug in Children with Glioma
DarkoStojanovic / Pixabay

A Planned Study Will Investigate the Effects of an Investigational Drug in Children with Glioma

A study is planned to investigate the effects of the experimental drug PTC596 in children with recently diagnosed diffuse intrinsic pontine glioma and high-grade glioma. The study is made up…

Continue Reading A Planned Study Will Investigate the Effects of an Investigational Drug in Children with Glioma
The FDA Have Approved Xtandi® as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
Source: Pixabay.com

The FDA Have Approved Xtandi® as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer

A drug to treat prostate cancer has been approved by the US Food and Drug Administration. The drug, Xtandi ® (enzalutamide), had previously been approved for castration-resistant prostate cancer (CRPC)…

Continue Reading The FDA Have Approved Xtandi® as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
There’s More Than One Way to Treat Cancer
Source: Pixabay.com

There’s More Than One Way to Treat Cancer

In an Article from AsiaOne.com, we meet John Ryan, retired nuclear reactor specialist who worked for the military when he was diagnosed with lung cancer. Now in remission he might…

Continue Reading There’s More Than One Way to Treat Cancer
Natural Killer Cells May Be Useful For Predicting How Patients Respond to Certain Immunotherapies, According to Recent Research
allinonemovie / Pixabay

Natural Killer Cells May Be Useful For Predicting How Patients Respond to Certain Immunotherapies, According to Recent Research

A recent study, published here in the journal Nature Medicine and used as the source for this article, has found that certain kinds of cells may be useful for predicting…

Continue Reading Natural Killer Cells May Be Useful For Predicting How Patients Respond to Certain Immunotherapies, According to Recent Research
Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released
stevepb / Pixabay

Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released

The drug Jakavi (ruxolitinib) is being investigated as a possible treatment for polycythemia vera (PV) and myelofibrosis. Results from studies into this were presented by Novartis at the 23rd Congress of…

Continue Reading Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released
The FDA has approved Keytruda For the Treatment of Refractory Primary Mediastinal Large B-cell Lymphoma
Source: Pixabay

The FDA has approved Keytruda For the Treatment of Refractory Primary Mediastinal Large B-cell Lymphoma

The U.S. Food and Drug Administration (FDA) has approved the medicine Keytruda for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, that have relapsed…

Continue Reading The FDA has approved Keytruda For the Treatment of Refractory Primary Mediastinal Large B-cell Lymphoma
The FDA Has Awarded Breakthrough Therapy Designation to an Experimental Drug for Treating Some Forms of Lung Cancer and Anaplastic Large Cell Lymphoma
Source: Pixabay

The FDA Has Awarded Breakthrough Therapy Designation to an Experimental Drug for Treating Some Forms of Lung Cancer and Anaplastic Large Cell Lymphoma

Pfizer has announced that the medicine Xalkori (crizotinib) has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for two potential treatment uses. The full article can be…

Continue Reading The FDA Has Awarded Breakthrough Therapy Designation to an Experimental Drug for Treating Some Forms of Lung Cancer and Anaplastic Large Cell Lymphoma
$2.6 million has Been Granted to Researchers Working on Reducing the Side-Effects of Checkpoint Inhibitor Immunotherapies For Cancer Patients
Source: Pixabay

$2.6 million has Been Granted to Researchers Working on Reducing the Side-Effects of Checkpoint Inhibitor Immunotherapies For Cancer Patients

The Melanoma Research Alliance (MRA) and The American Cancer Society (ACS) have announced the first recipients of their new research grants, reports PRNewswire. The grants have been set up as…

Continue Reading $2.6 million has Been Granted to Researchers Working on Reducing the Side-Effects of Checkpoint Inhibitor Immunotherapies For Cancer Patients